Next Article in Journal
Emerging and Dynamic Biomedical Uses of Ferritin
Next Article in Special Issue
Radiolabelled Aptamers for Theranostic Treatment of Cancer
Previous Article in Journal
Single-Blind Placebo-Controlled Response Test with Phenytoin 10% Cream in Neuropathic Pain Patients
Previous Article in Special Issue
Aptamer-iRNAs as Therapeutics for Cancer Treatment
Article Menu
Issue 4 (December) cover image

Export Article

Open AccessReview
Pharmaceuticals 2018, 11(4), 123;

TNBC Challenge: Oligonucleotide Aptamers for New Imaging and Therapy Modalities

Istituto per l’Endocrinologia e l’Oncologia Sperimentale G. Salvatore (IEOS), CNR, 80145 Naples, Italy
Istituto di Biostrutture e Bioimmagini, CNR, 80145 Naples, Italy
Author to whom correspondence should be addressed.
Received: 16 October 2018 / Revised: 2 November 2018 / Accepted: 9 November 2018 / Published: 13 November 2018
(This article belongs to the Special Issue Aptamer-Based Diagnostics and Therapeutics)
Full-Text   |   PDF [1536 KB, uploaded 13 November 2018]   |  


Compared to other breast cancers, triple-negative breast cancer (TNBC) usually affects younger patients, is larger in size, of higher grade and is biologically more aggressive. To date, conventional cytotoxic chemotherapy remains the only available treatment for TNBC because it lacks expression of the estrogen receptor (ER), progesterone receptor (PR) and epidermal growth factor receptor 2 (HER2), and no alternative targetable molecules have been identified so far. The high biological and clinical heterogeneity adds a further challenge to TNBC management and requires the identification of new biomarkers to improve detection by imaging, thus allowing the specific treatment of each individual TNBC subtype. The Systematic Evolution of Ligands by EXponential enrichment (SELEX) technique holds great promise to the search for novel targetable biomarkers, and aptamer-based molecular approaches have the potential to overcome obstacles of current imaging and therapy modalities. In this review, we highlight recent advances in oligonucleotide aptamers used as imaging and/or therapeutic agents in TNBC, discussing the potential options to discover, image and hit new actionable targets in TNBC. View Full-Text
Keywords: aptamer; chemoresistance; targeted imaging; targeted therapy; TNBC; tumor microenvironment; SELEX aptamer; chemoresistance; targeted imaging; targeted therapy; TNBC; tumor microenvironment; SELEX

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Camorani, S.; Fedele, M.; Zannetti, A.; Cerchia, L. TNBC Challenge: Oligonucleotide Aptamers for New Imaging and Therapy Modalities. Pharmaceuticals 2018, 11, 123.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top